Plain-English translation of NCT06466785 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called to see if it can treat anemia (low red blood cell counts) in people with advanced kidney disease who need dialysis. The medication will be compared to an existing anemia treatment called . About 429 patients will be randomly assigned to receive one of these two medications.
People with advanced kidney disease often develop anemia because their kidneys can't produce enough of a hormone that helps make red blood cells. This trial aims to see whether the new treatment can help restore healthy blood counts more effectively or safely than current options.
You likely qualify if…
You likely don't qualify if…
You will participate in a screening period of up to 4 weeks, then be randomly assigned to receive either the new medication () or the standard comparison medication () by injection. Starting from Day 1, you'll receive injections once or twice weekly for about a year, with doses adjusted to keep your blood counts in a healthy range. You'll have regular visits to the clinic where your blood will be checked, and you'll have a follow-up phone call 4 weeks after your last dose.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Armenia
Bulgaria